The Case for a Zero-For-Zero Tariff Agreement on Medtech
AdvaMed President and CEO Scott Whitaker is leading the call for a reciprocal “zero-for-zero” tariff agreement on medtech, urging the U.S. and its trading partners to eliminate tariffs on essential, lifesaving medtech products.
Why Medtech Products Are Essential and Non-Negotiable
In a recent interview with Joe Mullings, Scott made a compelling case for why medtech deserves a humanitarian exception in tariffs application:
“Medtech products are mandatory, not optional: If you need a pacemaker, you have to have a pacemaker – if you have an insulin pump, you have to wear your insulin pump. You can’t opt out because you want to wait a year, or the price goes up.”
Advocacy for U.S. Innovation and Patient Access
This conversation highlights AdvaMed’s ongoing advocacy with the Administration to exempt medtech products from tariffs in recognition of U.S.-led medtech innovation, research and development and manufacturing jobs and, most importantly, patient care.
Watch the Interview and Read Scott’s Op-Ed to Learn More
I encourage you to watch the full interview below and read Scott’s op-ed in The Baltimore Sun to learn more about why tariff-free trade is essential to maintaining the competitiveness of the medtech industry, keeping prices down, and ensuring patients have uninterrupted access to the technologies they need.
Greg Crist is chief advocacy officer and head of external affairs at AdvaMed, the medtech association, the world’s largest trade association representing medtech innovators.
Hear Patient Stories
The Story of Medtech empowers patients to share their experiences with medical technology in an effort to educate, inspire, and create community.